<DOC>
	<DOCNO>NCT00373087</DOCNO>
	<brief_summary>Entacapone antiparkinsonian drug block L-dopa metabolism , inhibit C-O-methyltransferase ( COMT ) enzyme . There individual variability COMT activity determine genetic polymorphism . The aim study investigate whether genetic variability influence entacapone efficacy Parkinson 's disease .</brief_summary>
	<brief_title>COMT Polymorphism Entacapone Efficacy</brief_title>
	<detailed_description>COMT protein dependent single autosomal locus two co-dominant allele high activity ( allele H ) low activity ( allele L ) form enzyme . L H allele frequency Caucasian population around 50 % . This monocentric randomize blind cross-over study compare acute challenge L-dopa + placebo versus L-dopa + 200 mg entacapone , Parkinson 's disease patient HH LL genotype .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Parkinson 's disease wear atypical parkinsonism neuroleptic use</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Catechol O-methyltransferase</keyword>
	<keyword>Entacapone</keyword>
	<keyword>pharmacogenetic</keyword>
</DOC>